Skip to main content

Market Overview

Wunderlich Securities Maintains Hold on Heartware


Wunderlich Securities is out with a research report on Heartware (NASDAQ: HTWR) and is maintaining its Hold rating and $80 price target on shares.

In a note to clients, Wunderlich writes, "Heartware (HTWR) provided an update of its ADVANCE bridge-to-transplant clinical trial Sunday during the EACTS Annual Meeting in Lisbon, Portugal. The update included data from the 140 patients in the ADVANCE trial and an additional 101 patients with at least six months of followup post implant from the Continued Access Protocol (CAP) allotments. The update was consisent with Heartware's June clinical update, showing reduced rates of thrombus requiring a pump exchange. The combined data suggest a thrombus rate under 5% is more likely for HVAD, which we believe will ease the concerns that arose back in April at the ISHLT meeting. We maintain our Hold rating and $80 target."

Shares of HTWR are off 26 cents to $67.20.


Related Articles (HTWR + CAP)

View Comments and Join the Discussion!

Posted-In: Wunderlich SecuritiesAnalyst Color Price Target Analyst Ratings

Latest Ratings

PHXSeaport GlobalInitiates Coverage On
AFCGLake StreetInitiates Coverage On29.0
OSSNoble Capital MarketsUpgrades7.0
NCNOGabelli & Co.Upgrades
HAECJS SecuritiesUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at